NVCR News and Press, NovoCure Limited From 01/13/20

January 13, 2020 Palm Beach, FL – January 13, 2020 – The global pain management devices market size is expected to reach USD 9.3 billion by 2026 registering a CAGR of 7.6%, according to a new study by Grand View Research, Inc. The global prevalence of diabetes i...

Novocure (NASDAQ: NVCR ) reports operating statistics and preliminary net revenues for Q4 and FY 2019. More news on: NovoCure Limited, Healthcare stocks news, Read more ...

Full year 2019 preliminary net revenues of $351.3 million, representing annual growth of 42 percent compared to 2018 Novocure to present at the 38 th Annual J.P. Morgan Healthcare Conference at 10:00 a.m. PST on Monday, Jan. 13, 2020 Fourth quarter and full year 2019 financial re...

My Sense of Risk is Heightened, Yet, We Could Run Much Higher for Longer. What To Do? I was hoping that this geopolitical brouhaha would moderate the rally to extend its life. A little reminder that stocks can go down as well as up is a very healthy lesson to reinforce. We need some weak...

SHANGHAI, China and ST. HELIER, Jersey, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology called Tumor ...

Shares of NovoCure (NASDAQ: NVCR) , which makes devices for treating cancerous solid tumors with electric fields, rocketed 152% higher last year, according to data from S&P Global Market Intelligence . That sizzling performance makes it one of last year's hottest healthcare stocks . Fo...

NovoCure (NVCR) is an innovative medical device company that is developing the fourth modality in cancer treatment. I rate NovoCure a buy . As the lead and only developer of Tumor Treating Field (TTField), the company has the potential to gain a significant share of the vast cancer treatm...

NovoCure ( NVCR ) is a name which I have followed with great interest, with the latest update dating back to November of 2018 as I concluded that it was an "interesting cure for the portfolio." 2019 has proven to be a great year with shares at some point having tripled from the 2018 levels...

Shares of Novocure (NASDAQ: NVCR) are down 9.3% at 3:37 p.m. EST, after being down down as much as 11.5% earlier in the day, after an analyst at Evercore ISI downgraded the medical-device maker to "in line." Considering how much Novocure's stock price has increased lately, the downgrade sho...

Baxter International (NYSE: BAX ) upgraded to Outperform with a $94 (12% upside) price target at Evercore ISI. Shares up  1%  premarket. More news on: Baxter International Inc., Henry Schein, Inc., Medtronic plc, Healthcare stocks news, Stocks on the move, , Read more ...